Azenta (NASDAQ:AZTA) Issues Earnings Results

Azenta (NASDAQ:AZTA) released its earnings results on Tuesday. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.17, FiscalAI reports. The company had revenue of $167.09 million for the quarter, compared to analysts’ expectations of $160.16 million. Azenta had a negative net margin of 26.86% and a positive return on equity of 1.37%.

Azenta Stock Down 6.7%

Azenta stock traded down $3.26 during midday trading on Thursday, reaching $45.64. 102,657 shares of the stock traded hands, compared to its average volume of 941,837. The stock’s fifty day moving average is $35.98 and its 200-day moving average is $28.51. Azenta has a 12 month low of $15.93 and a 12 month high of $50.06. The stock has a market cap of $2.00 billion, a P/E ratio of -12.50 and a beta of 1.47.

Trending Headlines about Azenta

Investors following AZTA have been watching these headlines:

• Positive Sentiment: Azenta reported fourth-quarter adjusted EPS of $0.28, ahead of the $0.11 consensus, and revenue of $167.09 million versus expectations of $160.16 million. The results helped fuel investor enthusiasm. Azenta fiscal 2026 results
• Positive Sentiment: Management forecast fiscal 2027 revenue of $648 million to $660 million, above the roughly $632 million analyst consensus, with organic growth of 3% to 5% and adjusted EBITDA margin expansion of about 200 to 250 basis points. This suggests improving growth and profitability momentum. Azenta fiscal 2027 guidance
• Negative Sentiment: Rosen Law Firm said it is investigating potential securities claims related to allegations that Azenta may have issued materially misleading business information. The announcement adds legal uncertainty, although it is an investigation notice rather than a reported finding of wrongdoing. Rosen Law Firm investigation notice

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Jefferies Financial Group upped their target price on shares of Azenta from $44.00 to $52.00 and gave the stock a “buy” rating in a report on Wednesday. Wall Street Zen lowered Azenta from a “buy” rating to a “hold” rating in a research note on Sunday, October 18th. Needham & Company LLC increased their target price on Azenta from $37.00 to $57.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Weiss Ratings raised Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 26th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $47.60.

About Azenta

Azenta, Inc. provides products and services for life sciences research and the management of biological samples. Its offerings include automated sample storage systems, laboratory automation equipment, consumables, and software used to track and manage samples. The company also provides genomic services through GENEWIZ, including sequencing and other genetic analysis services for researchers and organizations in the life sciences and pharmaceutical industries. Azenta was formed in 2021 when Brooks Automation separated its life sciences business and adopted the Azenta name.